Neoadjuvant chemotherapy with docetaxel, carboplatin and biosimilar trastuzumab in Her2-positive early breast cancer.

M. Oukkal,Souad Challal,Nawel Abed Benmelha,Nabil Benachenhou,Mohcen Wahib Boubnider,Amal Kouchkar,Nadia Terki,Ghania Benkhedda,Ghania Brahimi,Roza Belkaid,K. Bouzid

Neoadjuvant chemotherapy with docetaxel, carboplatin and biosimilar trastuzumab in Her2-positive early breast cancer.

2019

M. Oukkal
Souad Challal
Nawel Abed Benmelha
Nabil Benachenhou
Mohcen Wahib Boubnider
Amal Kouchkar
Nadia Terki
Ghania Benkhedda
Ghania Brahimi
Roza Belkaid
K. Bouzid

e12080Background: Evaluation of the histological response after neoadjuvant chemotherapy with Docetaxel-carboplatin and bio similar Trastuzumab (CANMAB 150mg) in Her2 positive breast cancer. The pr...

Keywords:

Trastuzumab
Biosimilar
Oncology
Carboplatin
HER2 Positive Breast Cancer
Pathology
Breast cancer
Internal medicine
Chemotherapy
Docetaxel
Medicine
early breast cancer
histological response

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations